Marshall Wace’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.65M | Sell |
210,070
-175,206
| -45% | -$2.35M | ﹤0.01% | 1626 |
|
|
2025
Q4 | $6.08M | Buy |
385,276
+109,887
| +40% | +$1.4M | 0.01% | 1072 |
|
|
2025
Q3 | $3.3M | Sell |
275,389
-582,023
| -68% | -$4.65M | ﹤0.01% | 1378 |
|
|
2025
Q2 | $6.48M | Buy |
857,412
+6,522
| +0.8% | +$39.2K | 0.01% | 1026 |
|
|
2025
Q1 | $4.7M | Sell |
850,890
-79,197
| -9% | -$489K | 0.01% | 1098 |
|
|
2024
Q4 | $5.35M | Buy |
930,087
+79,197
| +9% | +$759K | 0.01% | 1025 |
|
|
2024
Q3 | $8.82M | Sell |
850,890
-77,473
| -8% | -$1.01M | 0.01% | 799 |
|
|
2024
Q2 | $12M | Sell |
928,363
-22,699
| -2% | -$306K | 0.02% | 651 |
|
|
2024
Q1 | $16.6M | Buy |
+951,062
| New | +$12.6M | 0.03% | 580 |
|
|
2023
Q4 | – | Sell |
-74,810
| Closed | -$836K | – | 2280 |
|
|
2023
Q3 | $836K | Buy |
+74,810
| New | +$1.2M | ﹤0.01% | 1563 |
|
|
2022
Q3 | – | Sell |
-50,160
| Closed | -$2.37M | – | 3452 |
|
|
2022
Q2 | $2.37M | Buy |
+50,160
| New | +$2.72M | ﹤0.01% | 1874 |
|
|
2022
Q1 | – | Sell |
-9,670
| Closed | -$723K | – | 3511 |
|
|
2021
Q4 | $723K | Buy |
+9,670
| New | +$759K | ﹤0.01% | 2623 |
|
|
2021
Q1 | – | Sell |
-9,952
| Closed | -$419K | – | 2564 |
|
|
2020
Q4 | $419K | Sell |
9,952
-24,982
| -72% | -$1.1M | ﹤0.01% | 1540 |
|
|
2020
Q3 | $1.6M | Sell |
34,934
-96,890
| -73% | -$4.69M | 0.01% | 868 |
|
|
2020
Q2 | $6.62M | Sell |
131,824
-120,137
| -48% | -$6.22M | 0.05% | 394 |
|
|
2020
Q1 | $13M | Buy |
251,961
+70,906
| +39% | +$3.78M | 0.13% | 167 |
|
|
2019
Q4 | $11.2M | Buy |
181,055
+8,682
| +5% | +$538K | 0.08% | 301 |
|
|
2019
Q3 | $10.4M | Buy |
172,373
+18,587
| +12% | +$1.38M | 0.08% | 287 |
|
|
2019
Q2 | $13M | Buy |
153,786
+9,333
| +6% | +$840K | 0.11% | 216 |
|
|
2019
Q1 | $13.8M | Sell |
144,453
-7,438
| -5% | -$667K | 0.13% | 198 |
|
|
2018
Q4 | $10.8M | Buy |
151,891
+112,519
| +286% | +$8.63M | 0.11% | 225 |
|
|
2018
Q3 | $3.37M | Buy |
+39,372
| New | +$3.94M | 0.03% | 553 |
|
|
2015
Q3 | – | Sell |
-26,016
| Closed | -$1.17M | – | 958 |
|
|
2015
Q2 | $1.17M | Sell |
26,016
-97,441
| -79% | -$3.79M | 0.02% | 570 |
|
|
2015
Q1 | $3.78M | Sell |
123,457
-71,271
| -37% | -$2.77M | 0.05% | 367 |
|
|
2014
Q4 | $9.9M | Sell |
194,728
-121,698
| -38% | -$5.45M | 0.13% | 196 |
|
|
2014
Q3 | $12.5M | Buy |
316,426
+313,211
| +9,742% | +$12.5M | 0.18% | 152 |
|
|
2014
Q2 | $138K | Buy |
+3,215
| New | +$123K | ﹤0.01% | 885 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Marshall Wace's ENTA Position: Q1 2026 in Review
Marshall Wace reduced its Enanta Pharmaceuticals (ENTA) stake by 45% in Q1 2026, selling an estimated $2.35M and leaving 210,070 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1626.
Marshall Wace first reported a position in ENTA in Q2 2014 and has held it in 27 quarters since. The position peaked at $16.6M in Q1 2024. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Marshall Wace held 210,070 shares of Enanta Pharmaceuticals worth $2.65M as of Q1 2026.
- Marshall Wace sold 175,206 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.35M.
- Enanta Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1626 holding.
- Marshall Wace first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 27 quarters since.
- Marshall Wace's Enanta Pharmaceuticals position peaked at $16.6M in Q1 2024.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.